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Abstract
Receptor activity modifying proteins (RAMPs) associate with G-protein-coupled receptors 
(GPCRs) at the plasma membrane and together bind a variety of peptide ligands, serving as a 
communication interface between the extracellular and intracellular environments. The collection 
of RAMP-interacting GPCRs continues to expand and now consists of GPCRs from families A, B, 
and C, suggesting that RAMP activity is extremely prevalent. RAMP association with GPCRs can 
regulate GPCR function by altering ligand binding, receptor trafficking and desensitization, and 
downstream signaling pathways. Here, we elaborate on these RAMP-dependent mechanisms of 
GPCR regulation, which provide opportunities for pharmacological intervention.
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Introduction
G-protein-coupled receptors (GPCRs) constitute approximately 2% of the human genome 
and activate prominent cellular signaling pathways (Fredriksson et al., 2003). Due to their 
physiological importance and their cell surface localization, GPCRs are the most 
pharmacologically tractable proteins known. Approximately 40% of drugs currently 
marketed for the clinic target GPCRs (Rask-Andersen et al., 2011). However, only a small 
fraction of these receptors has been selected for drug development thus far, while the 
complex biology of the rest remain under intense study (Sexton et al., 2009).
Recently, there has been much excitement about the many modalities through which GPCR 
signals can be regulated, including: 1) biased agonism – differential signaling through a 
single receptor based on the bound ligand (Nagi and Pineyro, 2015); 2) allosteric modulation 
– changes in ligand affinity and efficacy by a substance bound to the receptor at a site 
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distinct from the orthosteric ligand binding site (Christopoulos, 2014); 3) pleiotropic 
signaling through different G-proteins and other non-G-proteins, such as arrestin; and 4) 
heterodimerization. The ability of GPCRs to homodimerize and to heterodimerize with 
different GPCRs and other proteins complicates GPCR biology. How GPCR oligomers 
affect signaling and function is of particular interest, as these protein-protein interactions 
may enable the development of drugs with very specific targets and effects (George et al., 
2002).
Receptor activity modifying proteins (RAMPs) are single-pass transmembrane proteins that 
heterodimerize with seven-transmembrane GPCRs belonging to each of the three main 
classes of GPCRs: the class A/Rhodopsin-like family, the largest of the three; the class B/
secretin family, containing the majority of identified RAMP-interacting GPCRs; and the 
class C family (Table 1). The association of RAMPs with GCPRs affects ligand specificity, 
receptor trafficking, receptor desensitization, and signaling capabilities, profoundly 
expanding the repertoire of targets available for modifying clinical disease. Since their 
discovery over 15 years ago, much has been learned about the effects of RAMPs on the 
function of some of their GPCR partners. However, a dearth of knowledge still exists 
regarding additional GPCR-RAMP pairs and, more importantly, the biological significance 
of both known and unknown GPCR-RAMP partners. Here, we discuss what is currently 
known about how RAMPs modulate GPCR activity and address what important questions 
remain.
RAMP discovery
RAMPs were first identified during an effort to understand signaling of the neuropeptide 
calcitonin (CT) gene-related peptide (CGRP). CGRP belongs to the CT peptide family, 
which consists of five peptide hormones: CGRP, CT, amylin (AMY), adrenomedullin (AM), 
and adrenomedullin 2/intermedin (AM2/IMD). These peptides have significant structural 
homology, and their often overlapping biological activities include gastric emptying (AMY, 
AM2/IMD), vasodilation (CGRP, AM, AM2/IMD), angiogenesis (CGRP, AM), and pain 
sensation (CGRP, CT) (Hong et al., 2012, Muff et al., 2004, Poyner et al., 2002). Despite 
sharing many physiological functions as well as affinity for GPCRs, different members of 
this peptide family mediate unique biological events, suggesting that they also must target 
specific and distinct receptors (Poyner et al., 2002).
Following the cloning of the GPCR CT receptor-like receptor (CLR), conflicting data 
emerged regarding whether the orphan receptor was able to bind CGRP. CLR exhibits 58% 
amino acid sequence similarity to the human CT receptor (CTR) and was therefore predicted 
to bind one of the CT family peptides (Fluhmann et al., 1995). Previous data suggested that 
CGRP acted through a Gαs-coupled GPCR to elicit cyclic AMP (cAMP) production (Seifert 
et al., 1985). However, transfection of human CLR or its rat homologue into COS-7 cells 
and subsequent CGRP treatment did not lead to cAMP accumulation (Fluhmann et al., 1995, 
Njuki et al., 1993). In contrast, when CLR was transfected into HEK293 cells, CGRP 
treatment elicited a 60-fold increase in cAMP production (Aiyar et al., 1996, Han et al., 
1997). Taken together, these data led to the speculation that HEK293 cells expressed an 
Klein et al. Page 2
Crit Rev Biochem Mol Biol. Author manuscript; available in PMC 2017 January 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
additional, endogenous factor that was required to activate the CGRP receptor, while COS-7 
cells did not express this factor.
Using an expression cloning approach, McLatchie and colleagues demonstrated that the 
CGRP receptor consists of a GPCR heterodimer: CLR and the 148 amino acid protein 
RAMP1 (McLatchie et al., 1998). Co-transfection of CLR and RAMP1 followed by CGRP 
treatment significantly increased cAMP production compared to transfection of either 
protein alone (McLatchie et al., 1998). Other studies demonstrated that cells expressing 
endogenous RAMPs can generate a cAMP response when transfected with CLR, whereas 
cell lines lacking endogenous RAMP1 cannot (Aiyar et al., 1996, Fluhmann et al., 1995, 
Njuki et al., 1993). Clearly, RAMP1 allows CLR to respond to CGRP. Subsequently, two 
additional RAMPs were identified and found to modify ligand specificity of CLR. While the 
CLR-RAMP1 complex binds CGRP, the CLR-RAMP2 and -3 complexes bind AM 
(McLatchie et al., 1998). These data established a novel mechanism for altering GPCR 
ligand specificity and illustrated the complexity of GPCR signaling, yielding a paradigm 
shift in the understanding of GPCR function (Hay et al., 2006, Parameswaran and Spielman, 
2006).
The RAMP family phylogenetic tree, assembled by TreeFam (TF333286), a database of the 
European Bioinformatics Institute, unveils 37% identity across 139 sequences from 53 
species (Figure 1). RAMP-expressing species are extremely diverse and include many model 
organisms, such as zebrafish, mice, rats, guinea pigs, and non-human primates. Other 
eutherians or placental mammals (cats, dogs, ferrets, pigs, horses, and humans) also express 
RAMPs, as do marsupials (platypuses and Tasmanian devils); ruminants (cattle); birds 
(chicken, turkeys); fish; reptiles (frogs, turtles) and endangered species (giant pandas, 
elephants, and dolphins). In the vast majority of these species, RAMPs 1–3 are encoded by 
single genes. However, the genomes of several bony fishes encode two Ramp1 and Ramp2 
genes, while RAMP3 is encoded by a single gene across all species and comprises a distinct 
outgroup to Ramp1 and Ramp2. Therefore, RAMP1 and RAMP2 are more closely related to 
each other than either protein is to RAMP3. To our knowledge, conservation of Ramp 
sequences across species has not been studied in depth, but further investigation into this 
topic could provide a lens through which we can interpret data and possibly use to explain 
functional differences between the three RAMPs.
Each RAMP has a large extracellular N-terminal domain, a single transmembrane domain, 
and a cytoplasmic C-terminus (McLatchie et al., 1998). Studies using RAMP chimeras that 
exchanged RAMP domains concluded that the N-terminus determines ligand specificity, 
while the C-terminus modifies downstream signaling for CLR- and CTR-based receptors 
(Fraser et al., 1999, Udawela et al., 2006). However, despite sharing a common structure, 
RAMP proteins have only 30% sequence homology. RAMPs 1 and 3 are 148 amino acids 
long, while RAMP2 is considerably larger at 175 amino acids (McLatchie et al., 1998). 
Ultimately, variations between the three RAMPs enable them to differentially affect GPCR 
ligand specificity; GPCR trafficking and internalization; and signaling capabilities.
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RAMP functionality
Ligand binding
As discussed above, the ability of RAMPs to modify CLR downstream signaling was 
essential to their discovery. Therefore, RAMP interaction with CLR has been particularly 
well-characterized. RAMP1 is necessary for CGRP binding, and RAMP2 or -3 facilitates 
AM binding (Figure 2A) (McLatchie et al., 1998). Crystal structures of the RAMP1 and -2 
extracellular domains both individually or together with the CLR extracellular domain 
revealed several intermolecular interactions specific to CLR-RAMP2 that could explain the 
ability of AM to bind this receptor complex. Subsequent photo-crosslinking and 
mutagenesis demonstrated specific residues in the N-terminus of RAMP2 that are required 
for AM binding. These are not conserved in RAMP1, indicating that the N-terminus serves 
to define the specificity for ligand binding (Kusano et al., 2008, Kusano et al., 2012).
Recently, Booe and colleagues solved the crystal structures of ligand-bound CLR-RAMP1 
and CLR-RAMP2 and determined that RAMPs dictate ligand specificity via two 
mechanisms: RAMPs alter the GPCR ligand binding pocket first by allosterically 
augmenting the binding site and second by offering distinct contact sites for ligand 
interaction (Booe et al., 2015). Remarkably, single amino acids anchor the peptide C-termini 
and enable strong binding of specific peptides (Trp 84 in RAMP1 for CGRP binding; Glu 
101 in RAMP2 for AM binding) (Booe et al., 2015). However, exchange of the C-terminal 
peptide residue between RAMP1 and -2 did not alter peptide binding, suggesting that 
additional mechanisms contribute to selectivity. Indeed, the crystal structures revealed that 
RAMP association with CLR allows for subtle changes in GPCR conformation that 
allosterically alter the CLR binding pocket. Whether the described RAMP residues are 
critical for determining ligand specificity for receptors other than CLR remains to be 
determined. Ultimately, these data demonstrate that subtle RAMP-induced changes in GPCR 
structure and ligand interactions can lead to dramatically different pharmacological profiles, 
providing support for future peptide-specific drug design (Booe et al., 2015).
Conversely, GPCR-RAMP associations may prevent ligand binding. For example, glucagon-
like peptide-1 (GLP-1) acts as a partial agonist when bound to the glucagon receptor 
(Weston et al., 2015). However, association of the glucagon receptor with RAMP2 blocks 
this partial agonism by preventing GLP-1 binding, though the specific mechanism 
underlying this effect is unknown (Weston et al., 2015).
Receptor trafficking
In addition to dictating ligand specificity, RAMPs also act as chaperones for CLR, as co-
expression of a RAMP is required for trafficking of CLR to the cell surface. Studies have 
shown that RAMPs have an endoplasmic reticulum (ER) retention signal within the C-
terminus (Steiner et al., 2002). RAMP association with CLR overrides this retention signal, 
allowing translocation of the CLR-RAMP complex from the ER to the plasma membrane. 
RAMPs are therefore critical for plasma membrane localization of some GPCRs.
RAMPs also perform a similar trafficking function for a family C receptor, calcium sensing 
receptor (CaSR). When transfected alone into COS-7 cells, CaSR is retained in the ER 
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(Bouschet et al., 2005). Co-expression of RAMP1 and RAMP3 with CaSR resulted in 
plasma membrane expression of CaSR, indicating that the CaSR-RAMP interaction 
promotes forward trafficking of CaSR to the cell surface (Bouschet et al., 2005). Although 
this finding elucidated a mechanism for CaSR regulation, these data in and of themselves 
were not groundbreaking. However, this was the first non-family B receptor identified to 
associate with RAMPs, opening the door to the possibility that RAMP effects are more 
pervasive than originally thought. A recent study has expanded this even further by 
identifying an association of RAMP3 with a class A receptor, GPR30, now known as G-
protein-coupled estrogen receptor 1 (GPER) (Lenhart et al., 2013).
In contrast to CLR and CaSR, CTR does not require a RAMP for cell surface localization 
(Figure 2B) (Poyner et al., 2002). However, CTR-RAMP interaction in the ER allows for 
formation of a functional AMY receptor at the plasma membrane. Like the receptors for the 
CT peptide family, the AMY receptors proved challenging to isolate (Hay et al., 2006). 
While AMY appeared to associate with CTR, CTR transfection into cell lines did not 
consistently yield convincing AMY ligand binding (Hay et al., 2006, Perry et al., 1997). 
Following the discovery of RAMPs, several groups suspected that these inconsistencies were 
due to cell-endogenous expression of RAMPs and subsequently demonstrated that CTR 
association with all three RAMPs forms AMY receptors (Armour et al., 1999, Christopoulos 
et al., 1999, Muff et al., 1999). Interactions of CTR with RAMPs 1–3 have been classified as 
AMY1–3, which display varying affinities for AMY (Poyner et al., 2002).
Receptor desensitization
Not only can RAMPs facilitate GPCR plasma membrane localization, but they can affect 
GPCR internalization once at the cell surface, providing an additional context for 
pharmacological intervention. For example, early studies demonstrated that CLR-RAMP2 
internalization was mediated by β-arrestin and dynamin (Hay et al., 2006, Hilairet et al., 
2001, Kuwasako et al., 2000). Later, bioluminescence resonance energy transfer (BRET) 
studies indicated that CLR agonist-mediated β-arrestin recruitment was dependent on the 
presence of RAMP1 (Heroux et al., 2007a). Whether this was true for other RAMPs was not 
investigated.
More recent studies have suggested unique protein trafficking roles for RAMP3. The C-
terminal tail of RAMP3 contains a type 1 PSD-95/Discs-large/ZO-1 (PDZ) domain that is 
absent in RAMP1 and -2. The PDZ domain allows for additional protein-protein interactions 
that alter receptor trafficking following receptor internalization. In contrast to the 
degradative pathway seen with RAMP1 and -2, Bomberger and colleagues showed that 
interaction of N-ethylmaleimide-sensitive factor (NSF) with the PDZ domain of RAMP3 
causes CLR to be recycled back to the cell surface, allowing for rapid receptor 
resensitization (Bomberger et al., 2005a). Additionally, interaction of the PDZ domain with 
the Na+/H+ exchange regulatory factor (NHERF) tethers the CLR-RAMP3 complex to the 
actin cytoskeleton and inhibits internalization of CLR (Bomberger et al., 2005b). In contrast, 
NHERF had no effect on CLR-RAMP1 or CLR-RAMP2 complexes that lack this PDZ 
domain.
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Cellular signaling
Because the discovery of RAMPs caused a major shift in the understanding of GPCR 
regulation, there was significant interest in other RAMP-interacting receptors. Given the 
structural similarities of family B GPCRs, such as CLR and CTR, and their affinity for 
peptide ligands, it stood to reason that other members of family B could interact with 
RAMPs. Using epitope-tagged constructs and immunofluorescence confocal microscopy, the 
Sexton laboratory discovered four novel GPCR-RAMP interactions (Christopoulos et al., 
2003). Co-transfection of the glucagon receptor, parathyroid hormone 1 receptor (PTH1R), 
parathyroid hormone 2 receptor (PTH2R), or vasoactive intestinal peptide 1 receptor 
(VPAC1R) with RAMPs resulted in cell surface expression of RAMPs, whereas RAMP-only 
transfection did not. Interestingly, not all of these receptors interacted with all of the 
members of the RAMP family. The glucagon receptor and PTH1R associated only with 
RAMP2; PTH2R associated only with RAMP3; and VPAC1R associated with all three 
RAMPs (Christopoulos et al., 2003).
Further analysis of VPAC1R revealed that the interaction of a single GPCR with different 
RAMPs can elicit different downstream signals. VPAC1R couples to multiple G-proteins 
and is therefore able to stimulate cAMP accumulation and phosphoinositide hydrolysis 
(Christopoulos et al., 2003). While treatment of cells co-transfected with VPAC1R and 
RAMP1 or -3 did not alter cAMP accumulation, co-transfection of VPAC1R and RAMP2 
enhanced phosphoinositide hydrolysis, suggesting that RAMP2 could modify G-protein 
coupling (Christopoulos et al., 2003). Whether this change in signaling is due to direct 
modification in G-protein coupling or due to changes in GPCR-RAMP localization remains 
to be determined (Sexton et al., 2012).
Studies of AMY1–3 offer evidence that RAMPs can indeed alter G-protein coupling. Morfis 
et al. observed that AMY treatment of cells co-transfected with CTR and RAMP1 or -3 
(AMY1 and AMY3, respectively) elicited a 20- to 30-fold increase in the potency of cAMP 
production compared to transfection of CTR alone (Morfis et al., 2008). Conversely, only a 
2- to 5-fold increase in the potency of intracellular Ca2+ production was observed, 
suggesting that AMY1 and AMY3 preferentially couple to Gαs versus Gαq relative to 
RAMP-independent CTR. Interestingly, while G-protein overexpression did not alter AMY 
binding in cells expressing CTR or CTR-RAMP1, overexpression of Gαs significantly 
increased AMY binding in CTR-RAMP2-expressing cells, and overexpression of Gαs and 
Gαq increased binding in CTR-RAMP3-expressing cells (Morfis et al., 2008). These data 
suggest that RAMPs are able to promote G-protein coupling compared to RAMP-
independent GPCRs.
RAMPs may also promote G-protein uncoupling. A new study demonstrates that glucagon-
mediated activation of the glucagon receptor is bolstered by co-expression of RAMP2 
(Weston et al., 2015). This effect is not due to greater affinity of glucagon for the glucagon 
receptor or trafficking of the GPCR to the plasma membrane (Weston et al., 2015). Rather, 
this RAMP2-dependent enhancement in glucagon receptor activation is due to uncoupling of 
the GPCR to Gαi, facilitating unchecked Gαs activation (Weston et al., 2015). However, 
glucagon receptor G-protein coupling is not only RAMP-dependent but also ligand-
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dependent; when the glucagon receptor-RAMP2 complex binds to a glucagon-related 
peptide, oxyntomodulin, Gαi coupling is unaffected (Weston et al., 2015).
Finally, RAMP association with a GPCR may alter coupling to G-proteins other than Gαs, 
Gαq, and Gαi. For example, RAMPs interact with vasoactive intestinal peptide 2 receptor 
(VPAC2R) and corticotrophin releasing factor receptor-1 (CRF1R) and alter G-protein 
coupling of both receptors (Wootten et al., 2013). Here, co-expression of RAMP1 and -2 
with VPAC2R in HEK293T and CHO-K1 cells significantly increased basal coupling to 
Gi/o/t/z compared with VPAC2R alone (Wootten et al., 2013). Similarly, co-expression of 
RAMP2 with CRF1R significantly enhanced Gi/o/t/z and Gq/11 coupling, leading to enhanced 
Ca2+ elevation in response to agonists (Wootten et al., 2013). Taken together, these data 
demonstrate the potential of RAMPs to alter downstream signaling, suggesting that an 
evaluation of the signaling profile is important to understanding the physiology of GPCR-
RAMP interactions.
RAMP physiology
While the repertoire of GPCR-RAMP pairs continues to expand, studies of RAMP 
physiology in animal models lag behind advances in RAMP biochemistry and pharmacology 
and have addressed only a subset of demonstrated GPCR-RAMP associations (Table 2) 
(Kadmiel et al., 2012). Knockout mouse models of all three RAMPs have been generated 
and phenotyped (Caron and Smithies, 2001, Dackor et al., 2007, Tsujikawa et al., 2007). 
Only RAMP2 deficiency is embryonic lethal at mid-gestation due to cardiovascular defects 
and a hypoproliferative lymphatic vasculature, implying that, despite their structural 
similarity and common association with several GPCRs, RAMPs 1 and 3 are unable to 
compensate for loss of RAMP2 (Caron and Smithies, 2001, Dackor et al., 2007, Tsujikawa 
et al., 2007). Therefore, studies of RAMP2 in mice are limited to conditional, tissue-specific 
deletions, Ramp2 heterozygotes, and Ramp2-overexpressing transgenic animals.
To date, animal studies of RAMP function have largely focused on the three CLR-RAMP 
pairs and their ligands, CGRP and AM, with particular emphasis on blood pressure 
regulation and cardioprotection. RAMP1 function has been expanded to include neuronal 
and pulmonary inflammation with therapeutic implications for migraine and asthma, both 
prevalent clinical problems (Li et al., 2014, Walker et al., 2015, Zhang et al., 2007). 
Additionally, Ramp2 heterozygotes display a constellation of endocrine abnormalities 
consistent with pituitary dysfunction and dysregulation of several GPCR-RAMP2 ligands, 
prompting the obligation to consider all RAMP-associated GPCRs and ligands when 
interpreting RAMP under- or overexpression phenotypes (Kadmiel et al., 2011). Similarly, 
we should be cognizant of GPCR-RAMP pairs outside of the class B GPCR family, as a 
study examining a novel interaction between RAMP3 and the class A receptor GPER in 
Ramp3−/− mice illustrates (Lenhart et al., 2013).
Conclusions
Together, these data highlight the unique effects that RAMPs have on GPCR function. Many 
GPCRs interact with several RAMPs. Therefore, it is important to define the individual 
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trafficking pathway, ligand affinity, and signaling profile of each GPCR-RAMP complex. 
Many additional RAMP effects remain undefined, so while the breadth of RAMP effects 
already seems widespread, we likely have only begun to uncover the capacity of RAMPs to 
alter GPCR physiology. However, it is worth noting that the majority of studies to date have 
not demonstrated direct interactions between GPCRs and RAMPs and that published 
observations about RAMP effects on GPCRs require further investigation.
Much remains to be understood about RAMP biochemistry and pharmacology. For example, 
the stoichiometry of GPCR-RAMP partners has been studied but is still debated. Evidence 
exists for a 1:1, 2:2, and 2:1 ratio of CLR-RAMP (Booe et al., 2015, Heroux et al., 2007b, 
Kusano et al., 2012, Watkins et al., 2013). However, whether the stoichiometry differs by 
cellular environment or between GPCRs is not known. These questions may be further 
complicated by the identification of RAMP-associating GPCR heterodimers. So far, studies 
have only focused on the interaction of one GPCR with one RAMP, but it is possible that 
two different GPCRs could complex with a RAMP, or two different RAMPs could bind to a 
single GPCR.
Figure 3 summarizes what is currently known about RAMP effects on GPCR function. In 
vitro biochemical studies have not only enabled the identification of novel GPCR-RAMP 
pairs but have also elucidated much about how RAMPs affect GPCR biology. GPCRs are 
pharmacologically tractable themselves, but the unique GPCR-RAMP interface may prove 
to be even more advantageous for the design of highly selective drugs (Sexton et al., 2009). 
Ultimately, in order to harness their potential as drug targets for disease, we must first 
understand how RAMPs affect physiology and what roles they play in physiological 
dysfunction in vivo.
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Figure 1. 
RAMP family phylogenetic tree. The RAMP family TreeFam (TF33386), assembled by a 
database of the European Bioinformatics Institute, contains 139 sequences from 53 species. 
Shown here is a condensed tree with a focus on model organisms and their relation to 
humans. Details on bioinformatic construction of this tree are provided in the literature 
(Guindon et al., 2010, Ruan et al., 2008). A color version of the figure is available online.
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Figure 2. 
Effects of RAMP association on CT receptor-like receptor (CLR) and CT receptor (CTR). 
(A) For cell surface expression, CLR requires the presence of one of the RAMP family 
members. CLR associates with RAMPs in the ER, facilitating plasma membrane expression. 
Association with RAMP1 yields a high affinity CT gene-related peptide (CGRP) receptor, 
whereas CLR association with RAMP2 or -3 results in a potent adrenomedullin (AM) 
receptor. (B) Conversely, CTR is trafficked to the plasma membrane independent of RAMPs. 
In the absence of a RAMP, CTR binds CT. In association with RAMP1, -2, -3, the CTR-
RAMP complex binds amylin (AMY). A color version of the figure is available online.
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Figure 3. 
Examples of effects of RAMP association on GPCR activity. GPCR-RAMP associations 
may promote GPCR plasma membrane localization; ligand specificity; functional 
selectivity; and trafficking. Receptor chaperone and ligand specificity: RAMPs can enable 
GPCRs to shuttle to the plasma membrane, and differential RAMP association may dictate 
preference for endogenous ligands. For example, RAMP association with CT receptor-like 
receptor (CLR) in the endoplasmic reticulum promotes localization of CLR at the plasma 
membrane, where CLR-RAMP1 can bind CT gene-related peptide (CGRP), and CLR-
RAMP2 or –RAMP3 can bind adrenomedullin (AM). Functional selectivity: Depending on 
the GPCR-RAMP association, GPCRs may preferentially couple to certain G-proteins, such 
as Gs, Gq, and Gi, or other non-G-proteins, such as β-arrestin. For example, corticotrophin 
releasing factor receptor-1 (CRF1R)-RAMP2 preferentially couples to Gi/o/t/z and Gq/11. 
Receptor trafficking: GPCR-RAMP associations may affect whether the GPCR is degraded 
or recycled back to the plasma membrane following internalization. For example, RAMP3 
contains a PSD-95/Discs-large/ZO-1 (PDZ) domain that interacts with N-ethylmaleimide-
sensitive factor (NSF) to shunt CLR away from the degradative pathway it enters following 
internalization when associated with RAMP1 or RAMP2. ?: Other effects of GPCR-RAMP 
associations remain to be discovered. A color version of the figure is available online.
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Table 1
RAMP-associating GPCRs.
Receptor Family GPCR Associating RAMPs
A GPER RAMP3
B CLR
RAMP1
RAMP2
RAMP3
B CTR
RAMP1
RAMP2
RAMP3
B CRF RAMP2
B Glucagon Receptor RAMP2
B PTH1R RAMP2
B PTH2R RAMP3
B Secretin Receptor RAMP3
B VPAC1R
RAMP1
RAMP2
RAMP3
B VPAC2R
RAMP1
RAMP2
RAMP3
C CaSR RAMP1RAMP3
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